CAMP4 Therapeutics Corporation announced its financial results for the full year ended December 31, 2024, alongside a corporate update. The company reported a net loss of $51.8 million for the year, compared to $49.3 million in 2023. Research and development expenses decreased to $38.8 million from $40.6 million in the prior year, while general and administrative expenses increased to $14.9 million from $11.6 million.
As of December 31, 2024, CAMP4 held approximately $64.0 million in cash and cash equivalents, which the company believes will fund its planned activities into the second quarter of 2026. This cash position is crucial for supporting ongoing clinical and preclinical development.
Operationally, the Phase 1 clinical trial of CMP-CPS-001 for Urea Cycle Disorders (UCDs) is ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts. Safety, pharmacokinetic, and pharmacodynamic data from this trial are anticipated in Q4 2025. The company plans to initiate an expansion into a Phase 1b clinical trial in female OTC heterozygotes in Q2 2025, targeting an underserved patient population. Additionally, CMP-SYNGAP-01 was nominated as a development candidate for SYNGAP1-related disorders, with GLP toxicology studies expected to commence in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.